Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Anaplastic Thyroid Carcinoma

Posterior reversible encephalopathy syndrome (PRES) is a rare reversible neurological syndrome that causes subcortical vasogenic brain edema and which is associated with the use of target-specific agents. Lenvatinib is a target-specific agent that was recently approved for inoperable thyroid cancer....

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Yoko, Gozawa, Rikako, Koyama, Keisuke, Nakayama, Takeo, Sagoh, Tadashi, Sunaga, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919864/
https://www.ncbi.nlm.nih.gov/pubmed/29225265
http://dx.doi.org/10.2169/internalmedicine.9593-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919864/
https://www.ncbi.nlm.nih.gov/pubmed/29225265
http://dx.doi.org/10.2169/internalmedicine.9593-17

Ejemplares similares